Johnson & Johnson said its Janssen Therapeutics affiliate reached a preliminary collaboration agreement with the U.S. Agency for International Development to expand access to its drug to treat a form of resistant tuberculosis that is uncommon in the U.S. but growing globally.

The drug, Sirturo, was granted accelerated approval by the U.S. Food and Drug Administration nearly two years ago to treat patients with multidrug-resistant...